Please assess the completion status of the following clinical trial:

Trial Title: Proof of Mechanism in ELT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Heterosexual male subject with self-reported moderate or severe primary Premature ejaculation with ejaculation occurring on or before penetration, or shortly there after with minimal stimulation~* Baseline Ejaculation Latency time \< 3 minutes~* Subjects must agree to use a contraception methods as per protocol~* Body weight \> or = 50 kg and Body Mass Index within the range 19.0-29.9 Kg/m2~* Subject with normal visual acuity (with appropriate correction if needed)~* Subject able to cooperate in all study procedure including the eye examination with use of mydriatics~Exclusion Criteria:~* Erectile dysfunction~* History of migraine~* Current clinically relevant abnormality~* History of psychiatric illness or suicidal attempts or behaviours~* History of any eye disorder or colour blind, excluding myopia and presbyopia~* Cardiac conduction disorder or other clinically significant cardiac disease~* Positive at pre-study drug/alcohol screen and to Hepatitis or HIV tests~* Regular consumption of alcohol~* History of sensitivity or intolerance to drugs~* Consumption of red wine, seville oranges, grapefruit or grapefruit juice \[and/or pummelos, exotic citrus fruits, grapefruit hybrids\] from 7 days prior to the first dose of study medication~* Subject has received or is continuing to receive any treatment for premature ejaculation in the four weeks prior to the study start~* Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements prior to the first dose of study medication~* Participation in another clinical trial in the previous month~* Exposure to more than four new experimental drugs within the previous 12 months~* Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.~* Unwillingness or inability to follow the procedures outlined in the protocol.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- GSK958108 3 mg (Type: EXPERIMENTAL): Experimental
- Placebo of GSK958108 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).